All In Biotech

Drug Trial Radar · NCT07519772

A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)

A Phase 1b/2 Study to Evaluate the Safety and Efficacy of MK-1045 Monotherapy or in Combination With Other Anticancer Agents in Participants With Non-Hodgkin Lymphoma

Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

May 3, 2026

Primary completion

Jul 1, 2030

Study completion Apr 1, 2031

Sponsor

Lead sponsor
Merck Sharp & Dohme LLCMerck & Co. (MRK)
Sponsor type
Industry
First posted
Apr 9, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Researchers are looking for new ways to treat 2 types of non-Hodgkin lymphoma (NHL) called follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL). FL is a slow-growing type of NHL. DLBCL is a fast-growing type of NHL. NHL is a cancer in the lymphatic system that causes swollen lymph nodes. The lymphatic system is part of the immune system. In this study, researchers want to learn if MK-1045 can treat FL and DLBCL. MK-1045 is a study treatment that is an immunotherapy, which helps the immune system fight cancer. The goals of this study are to learn how safe MK-1045 is and if people tolerate it. Researchers also want to see if FL and DLBCL respond (the cancer gets smaller or goes away) to treatment.

Conditions

  • Lymphoma, Non-Hodgkin
  • Lymphoma, Follicular
  • Lymphoma, Large B-Cell, Diffuse

Interventions

  • MK-1045Biological

    Intravenous (IV) Infusion or Subcutaneous (SC) injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants Who Experience an Adverse Event (AE)Time frame: Up to approximately 49 months
  2. Number of Participants Who Discontinue Study Treatment Due to an AETime frame: Up to approximately 12 months
  3. Arms 2 and 3: Number of Participants Who Experience Dose Limiting Toxicity (DLT)Time frame: Up to approximately 28 days
  4. Arms 1, 2, and 4: Objective Response Rate (ORR) per Lugano Response Criteria as assessed by Blinded Independent Central review (BICR)Time frame: Up to approximately 49 months

Locations

56 sites in 16 countries. Site status is shown where the registry gives one.

  • Cedar Sinai Cancer Center ( Site 0119)

    Los Angeles, California · Recruiting

  • Colorado Blood Cancer Institute ( Site 7000)

    Denver, Colorado · Recruiting

  • University Hospitals of Cleveland ( Site 0113)

    Cleveland, Ohio · Recruiting

  • SCRI Oncology Partners ( Site 0100)

    Nashville, Tennessee · Recruiting

  • Henry-Joyce Cancer Clinic ( Site 0115)

    Nashville, Tennessee · Recruiting

  • Hospital Aleman ( Site 1400)

    CABA, Argentina · Recruiting

  • Instituto Alexander Fleming ( Site 1404)

    Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting

  • Hospital Universitario Austral ( Site 1402)

    Pilar, Buenos Aires, Argentina · Recruiting

  • Sanatorio Nuestra Senora del Rosario ( Site 1403)

    Rosario, Santa Fe Province, Argentina · Recruiting

  • Townsville University Hospital ( Site 0204)

    Townsville, Queensland, Australia · Recruiting

  • Royal Adelaide Hospital ( Site 0205)

    Adelaide, South Australia, Australia · Recruiting

  • Box Hill Hospital ( Site 0202)

    Box Hill, Victoria, Australia · Recruiting

  • Hospital Paulistano ( Site 1504)

    São Paulo, Brazil · Recruiting

  • Hospital Erasto Gaertner ( Site 1503)

    Curitiba, Paraná, Brazil · Recruiting

  • Hospital das Clinicas FMUSP ( Site 1502)

    São Paulo, São Paulo, Brazil · Recruiting

  • Princess Margaret Cancer Centre ( Site 0301)

    Toronto, Ontario, Canada · Recruiting

  • Hopital Maisonneuve-Rosemont CIUSSS de l Est de L Ile de Montreal ( Site 0305)

    Montreal, Quebec, Canada · Recruiting

  • Clínica Alemana de Santiago ( Site 1608)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Pontificia Universidad Catolica de Chile-CICUC ( Site 1603)

    Santiago, Region M. de Santiago, Chile · Recruiting

  • Beijing Cancer hospital ( Site 1701)

    Beijing, Beijing Municipality, China · Recruiting

  • Fujian Provincial Cancer Hospital.. ( Site 1704)

    Fuzhou, Fujian, China · Recruiting

  • Sun Yat-Sen University Cancer Center ( Site 1712)

    Guangzhou, Guangdong, China · Recruiting

  • Henan Cancer Hospital ( Site 1702)

    Zhengzhou, Henan, China · Recruiting

  • Fudan University Shanghai Cancer Center ( Site 1711)

    Shanghai, Shanghai Municipality, China · Recruiting

  • Centre Hospitalier Universitaire de Nice - Hôpital l'Archet ( Site 0400)

    Nice, Alpes-Maritimes, France · Recruiting

  • Hopital Saint Louis ( Site 0405)

    Paris, Île-de-France Region, France · Recruiting

  • CHU Estaing ( Site 0403)

    Clermont-Ferrand, Puy-de-Dome, France · Recruiting

  • UKGM Gießen/Marburg ( Site 0505)

    Giessen, Hesse, Germany · Recruiting

  • Universitatsklinikum Essen AoR ( Site 0507)

    Essen, North Rhine-Westphalia, Germany · Recruiting

  • Carmel Hospital ( Site 0602)

    Haifa, Israel · Recruiting

  • Shaare Zedek Medical Center ( Site 0603)

    Jerusalem, Israel · Recruiting

  • Haddasah Medical Center ( Site 0600)

    Jerusalem, Israel · Recruiting

  • Sheba Medical Center ( Site 0601)

    Ramat Gan, Israel · Recruiting

  • Sourasky Medical Center. ( Site 0604)

    Tel Aviv, Israel · Recruiting

  • Istituto Europeo di Oncologia IRCCS ( Site 0702)

    Milan, Italy · Recruiting

  • Fondazione Policlinico Universitario Agostino Gemelli ( Site 0705)

    Roma, Italy · Recruiting

  • Istituto Nazionale Tumori IRCCS Fondazione Pascale-SC Ematologia Oncologica ( Site 0700)

    Campania, Napoli, Italy · Recruiting

  • INOC - Istituto Nazionale Oncologico Candiolo ( Site 0701)

    Candiolo, Piedmont, Italy · Recruiting

  • Pratia MCM Krakow ( Site 0903)

    Krakow, Lesser Poland Voivodeship, Poland · Recruiting

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworów Układu Chłonnego ( Site 0900)

    Warsaw, Masovian Voivodeship, Poland · Recruiting

Showing 40 of 56 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.